<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00364234</url>
  </required_header>
  <id_info>
    <org_study_id>R21 DK74105 (completed)</org_study_id>
    <nct_id>NCT00364234</nct_id>
  </id_info>
  <brief_title>Low Magnitude Mechanical Stimuli Effects on Bone Structure in ESRD</brief_title>
  <official_title>Low Magnitute Mechanical Stimuli Effects on Bone Structure in ESRD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed 6 month pilot and feasibility randomized trial will evaluate LMMS as an anabolic&#xD;
      stimulus to bone in 30 adults on maintenance hemodialysis. The intervention will consist of&#xD;
      20 minute daily sessions in the home standing on an active LMMS platform or a placebo device&#xD;
      that emits an audible hum suggestive of an active device. Each device contains an electronic&#xD;
      monitor that documents adherence. The study will examine trabecular bone volume fraction&#xD;
      (bone volume/total volume, BV/TV %) and architecture using microMRI, and cortical volumetric&#xD;
      BMD and dimensions using QCT at baseline and 6 months. The hypothesis is that active LMMS&#xD;
      will results in greater mean changes in trabecular and cortical parameters in hemodialysis&#xD;
      patients. The proposed study will test the feasibility of conducting the intervention in&#xD;
      dialysis patients and will generate preliminary data on rates of change in trabecular and&#xD;
      cortical parameters in the active and placebo groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Renal osteodystrophy (ROD) is a multifactorial and pervasive disorder in chronic kidney&#xD;
      disease (CKD). As renal failure progresses, ensuing abnormal parathyroid hormone (PTH)&#xD;
      secretion and mineral metabolism result in sclerosis of trabecular bone, thinning of cortical&#xD;
      bone, and increased cortical porosity.(1) Despite the widespread use of phosphate binders and&#xD;
      vitamin D therapies, hip fracture rates and mortality risk following fractures are markedly&#xD;
      greater in dialysis patients, compared with the general population.&#xD;
&#xD;
      The vast majority of studies of bone loss in CKD relied on dual energy x-ray absorptiometry&#xD;
      (DXA) measures of bone mineral density (BMD). However, DXA summarizes the total bone mass&#xD;
      within the projected bone area, concealing disease effects on trabecular and cortical bone.&#xD;
      For example, in high-turnover ROD, increased trabecular volume may offset cortical bone loss,&#xD;
      resulting in normal or increased areal-BMD despite poor bone strength. Quantitative computed&#xD;
      tomography (QCT) enables discrete assessment of trabecular and cortical volumetric BMD and&#xD;
      dimensions. However, this is an incomplete solution in the setting of CKD because QCT does&#xD;
      not assess trabecular architecture. Micro-magnetic resonance imaging (µMRI) provides a&#xD;
      non-invasive technique to assess trabecular architecture. The µMRI data are quantified by 3D&#xD;
      digital processing methods, such as topological analysis, to determine trabecular properties.&#xD;
      Our pilot study of µMRI in dialysis patients revealed significant reductions in cortical&#xD;
      thickness and suggested deterioration in the trabecular network. This innovative imaging&#xD;
      modality may be uniquely suited to the assessment of ROD therapies.&#xD;
&#xD;
      Mechanical forces on the skeleton arise from muscle contraction and these forces generate&#xD;
      signals that modulate bone architecture. Animal studies demonstrated that daily exposure to&#xD;
      low magnitude mechanical stimuli (LMMS) enhanced trabecular and cortical bone quantity and&#xD;
      quality. A randomized trial of LMMS in post-menopausal women demonstrated that LMMS were&#xD;
      associated with increased DXA BMD, without adverse effects. LMMS may be uniquely suited to&#xD;
      restore cortical and trabecular bone structure in ROD.&#xD;
&#xD;
      The study will enroll adults, ages 21-65 years, treated with maintenance hemodialysis at&#xD;
      UPENN. The study will exclude the elderly and subjects with major co-morbid conditions in&#xD;
      order to increase the likelihood that subjects will complete the 6 month intervention without&#xD;
      significant interruptions due to hospitalization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trabecular Microarchitecture</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Renal Osteodystrophy</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low magnitude mechanical stimuli</intervention_name>
    <description>20 minutes standing on low magnitude high frequency vibrating platform</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ages 21-65 years&#xD;
&#xD;
          -  Maintenance Hemodialysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active Malignancy&#xD;
&#xD;
          -  History of myocardial infarction&#xD;
&#xD;
          -  Congestive heart failure III-IV stage&#xD;
&#xD;
          -  Cerebrovascular disease&#xD;
&#xD;
          -  Planned relocation&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Anticipated living-donor transplantation within the coming 6 months&#xD;
&#xD;
          -  Liver failure&#xD;
&#xD;
          -  Neuropathies&#xD;
&#xD;
          -  Prior lower extremity amputation or difficult with ambulation&#xD;
&#xD;
          -  History of hip fracture&#xD;
&#xD;
          -  History of hip replacement&#xD;
&#xD;
          -  History of orthostatic hypotension or a balance disorder&#xD;
&#xD;
          -  History of a fall within 6 months prior to enrollment&#xD;
&#xD;
          -  Difficulty in ambulation will be defined as difficulty climbing two flights of stairs&#xD;
             or walking three blocks&#xD;
&#xD;
          -  Patients with pacemaker or other metal implants that are contraindicated for MRI scans&#xD;
&#xD;
          -  Weight &gt; 113kg&#xD;
&#xD;
          -  HIV Positive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary B Leonard, MD, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia , Philadelphia, Pennsylvania, United States</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childen's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>August 14, 2006</study_first_submitted>
  <study_first_submitted_qc>August 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <last_update_submitted>April 13, 2015</last_update_submitted>
  <last_update_submitted_qc>April 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <name_title>Mary Leonard, MD, MSCE, Associate Professor of Pediatrics and Epidemiology</name_title>
    <organization>Children's Hospital of Philadelphia</organization>
  </responsible_party>
  <keyword>Renal Osteodystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Kidney Disease-Mineral and Bone Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

